At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,153 enrolled
Drug / intervention
Lebrikizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab for Atopic Dermatitis. Completed, enrolled 1,153 participants across 321 sites in 16 countries.
Detailed Summary
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Bulgaria, Canada, Estonia, France, Germany, Latvia, Lithuania, Mexico, Poland, Singapore, South Korea, Spain, Taiwan, Ukraine, United States
CollaboratorsDermira, Inc.
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionJul 2024
Study CompletionApr 2025
TodayJul 2026
First PostedMay 18, 2020
Enrollment StartJun 15, 2020
Primary CompletionJul 19, 2024
Study CompletionApr 22, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.1 years ago
Interventions
Lebrikizumabbiological
Subcutaneous injection